.After elevating $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the public market.The Eli Lilly-partnered biotech want to list on the Nasdaq under the icon “BIOA,” according to documentations filed along with the Securities as well as Swap Payment. The provider has certainly not publicly discussed an expected monetary quantity for the offering.The clinical-stage company boasts lead candidate azelaprag, an orally supplied little particle slated to enter period 2 testing in combo along with semaglutide– marketed through Novo Nordisk under trademark name Wegovy for weight-loss– in the 1st fifty percent of upcoming year. Semaglutide is actually also marketed as Ozempic as well as Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is actually developed to mix effectively with GLP-1 drugs, increasing weight loss while preserving muscular tissue mass. The investigational drug was discovered to become well-tolerated among 265 people around 8 period 1 tests, depending on to BioAge.Recently, BioAge amassed the help of Lilly to manage a test combining azelaprag with the Huge Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro and also Zepbound for effective weight loss. The companions are presently carrying out a phase 2 trial of azelaprag as well as tirzepatide, with topline outcomes assumed in the third one-fourth of 2025.The biotech is actually additionally planning a the hormone insulin sensitivity proof-of-concept test examining azelaprag as a monotherapy in the 1st fifty percent of upcoming year to sustain prospective indicator expansion.
In addition, the provider prepares to inquire the FDA for authorization in the 2nd half of 2025 to introduce individual screening for an NLRP3 prevention targeting metabolic diseases as well as neuroinflammation.BioAge’s expected relocate to the public market observes a mild uptick in prepared biotech IPOs coming from Bicara Therapies and Zenas Biopharma. Zooming out, the latest IPO yard is actually a “mixed photo,” along with top quality business still debuting on the general public markets, only in minimized amounts, according to PitchBook.